Given shares were jumping 25% to $29.61 while Covidien was adding 0.5% to $68.38.
Covidien regularly makes large acquisitions to enter new markets and this summer spun off its pharmaceutical business, Mallinckrodt LLC, to focus on medical devices. Two years ago it paid $2.6 billion to acquire ev3, to move into vascular procedures. Ev3 makes devices for endovascular surgeries.
Covidien turned to Meitar for legal advice including Dan Shamgar and Mike Rimon. The company's in-house corporate counsel is Matt Nicolella.
A Barclays team including Doug Solomon, Jed Brody and Soraya Scroggins provided financial advice to Given, while legal counsel was provided by Kirkland & Ellis LLP's David Fox, Daniel Wolf, Yi Claire Sheng, Scott Price, Mark Kovner and Daniel Tavakoli.